The rebound of infant formula demand in China, P&G's launch of VÖOST Vitamins in Singapore, positive findings of a beta-glucan supplement on COVID-19 patients are some of the most-read stories in February.
China's corporate daigou channel is witnessing high growth momentum and demand for infant formulas is exceeding pre-COVID-19 levels, according to Australian infant formula maker Bubs.
The Procter & Gamble Company (P&G) has launched VÖOST Vitamins, an Australian effervescent supplement brand, in major retailers in Singapore after acquiring the brand in April 2021.
The combination of two beta-glucans produced by Aureobasidium Pullulans (AFO-202 and N-163) strains along with standard treatment was shown to reduce inflammatory biomarkers in COVID-19 patients, compared to just the standard treatment alone.
An investigation into the adulteration of herbal weight loss supplements sold in the United Arab Emirates (UAE) found 17% of such products contain illegally added pharmaceuticals or prescription medicines.
Singapore nicotinamide mononucleotide (NMN) brand For Youth is launching a saliva test kit which claims to measure an individual's biological age.
One of the world's largest spice producers, Synthite, has set sights on becoming a global nutraceutical consumer brand, with its market expansion plans gathering pace.
Evidence from the Furukawa Nutrition and Health Study in Japan found no association between green tea consumption and symptoms of depression.
Flavettes, a brand by Malaysia-headquartered Duopharma Biotech, is moving a step further into the health and beauty segment by incorporating well-known beauty ingredients such as hyaluronic acid, ceramide, and collagen peptide into effervescent tablets.
House Wellness Foods is eyeing expansion in the Australian and New Zealand markets after its flagship postbiotic has been recognised as a non-novel food by the local authorities.
The quality of clinical trials behind products under Japan's Foods with Function Claims (FFCs) is undermined by a lack of proper protocols, such as the absence of trial registration and transparent study designs, says a new study.